Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).
RemeGen Co., Ltd. has announced its 2025 second extraordinary general meeting (EGM) scheduled for April 2, 2025, where the primary agenda is to consider and approve the appointment of Mr. Wen Qingkai as an executive director. This appointment could potentially influence the company’s strategic direction and governance, impacting stakeholders and possibly enhancing its industry positioning.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry. The company focuses on developing innovative therapies and products, with a market emphasis on biopharmaceutical advancements.
YTD Price Performance: 8.89%
Average Trading Volume: 2,364,601
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$14.88B
See more data about 9995 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue